INTRODUCTION
Survivors of adult-onset cancer are at risk of developing second primary cancers (SPCs) 1, 2 and have been reported to have a 7% to 36% higher cancer risk than expected in the general population. [3] [4] [5] [6] [7] Our recent systematic review of temporal changes in subsequent cancer risk indicated an increasing trend in risk among adult cancer survivors from the 1980s to 2000 when considering studies from the United States and Australia but not from elsewhere. 8 However, to the best of our knowledge, few studies have >20 years' surveillance with which to assess time patterns on overall SPC risks into the most recent era. 5 Factors associated with changing trends in SPC risk might include the increased detection of SPCs and changing patterns of cancer treatment or other shared carcinogenic factors (eg, tobacco and/or alcohol consumption). Both radiotherapy and chemotherapy can induce treatment-related cancers but evidence suggests this explains only a relatively small percentage of SPCs in adults. 9, 10 Cancer survivors tend to undergo repeated medical imaging for the evaluation of treatment response and posttreatment surveillance. In addition, they may receive more frequent screening for new cancers than individuals without a history of cancer. 11 Although patients are expected to benefit from follow-up care, they also may be more likely to have indolent cancers or "incidentalomas" detected, leading to cancer overdiagnosis. 12 The use of diagnostic imaging and cancer screening tests has increased sharply in Australia and other developed countries (eg, the United States) since the 1980s. [13] [14] [15] Studies from Australia and the United States have observed a gradual increase in SPC risk over the period between 1982 and 2001 and 1973 and 2000 as a potential consequence. 3, 4 It is unclear whether the risk of SPCs has continued to increase since then.
To better understand trends in SPC risk, the objectives of the current study were to 1) investigate changes in SPC risk over time in survivors of adult-onset cancer in Tasmania, an island state of Australia with limited outmigration 16 ; and 2) assess any changes in SPC burden in survivors of specific types of first cancer during the recent 30 years.
MATERIALS AND METHODS

Study Population
This study included 51,802 patients with cancer identified in the Tasmanian Cancer Registry (TCR). These individuals were diagnosed with a first cancer at age 15 years from 1980 to 2009, and survived at least 2 months. Follow-up of the cohort ended on December 31, 2013. The TCR is a population-based registry covering the entire state. The majority of registered cases include data from both pathology laboratories and hospital services (inpatient or radiation oncology clinic). 17 Access to deidentified records was approved by the Tasmanian Health and Medical Human Research Ethics Committee.
Ascertainment of SPCs
Ascertainment of SPCs followed the International Rules for Multiple Primary Cancers (International Classification of Diseases for Oncology, Third Edition [ICD-O3]) proposed by the International Association of Cancer Registries and the International Agency for Research on Cancer (IARC). 18 SPCs occurring within 2 months of the date of the first cancer diagnosis were excluded to reduce detection bias. Site and morphology for first primary cancers and SPCs were coded using the ICD-O3. Cancers of different sites were grouped as shown in Table 1 . We only included cases of invasive cancer; cases of benign tumors, cancers in situ, or of uncertain behavior all were excluded. Nonmelanoma skin cancers also were excluded because they are not routinely registered in the TCR.
Statistical Analysis
Using a standard person-years approach, 19, 20 person-years at risk (PYR) was assessed from 2 months after the first cancer diagnosis to the date of the second cancer diagnosis, the date of death, or the end of follow-up (December 31, 2013), whichever came first. PYR for each patient in the study cohort were accumulated within specific sex, 5-year age group, and 1-year calendar period strata. The expected number of SPCs was calculated using PYR within strata multiplied by corresponding site-specific cancer incidence rates in the Tasmanian population.
Comparisons with the general population
Standardized incidence ratios (SIRs) were calculated as the ratios of observed to expected numbers of SPCs. Poisson regression models were used to derive 95% confidence intervals (95% CIs) of SIRs, assuming that the observed number followed a Poisson distribution. 3, 19, 20 It has been suggested that including SPCs occurring in the same site as the first cancer leads to underestimation of SIRs for all sites of SPC combined. 21 To maintain consistency with IARC coding rules that neoplasms diagnosed simultaneously in the same site of different morphology should be regarded as multiple cancers, we aimed herein to describe the risk of all SPCs rather than second discordant primary cancers. SIRs were stratified by first cancer types, second cancer types, and calendar year of first cancer diagnosis at 5-year intervals (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, and 2005-2009 ). Absolute excess risks (AERs) were calculated by subtracting the expected number of second cancers from the observed number and then dividing by 10,000 person-years ([observed-expected]/[PYR 3 10,000]). 3, 22 The AER is interpreted as the absolute measure of SPC burden in a specific population of cancer survivors. 3, 23 For survivors of specific first cancer types, we computed the SIRs and AERs by 3 calendar periods of first cancer diagnosis (1980-1989, 1990-1999, and 2000-2009) to identify the types of SPC that contributed to changes in the SPC burden during the recent 30 years.
Internal comparisons within the study cohort
We used multivariable Poisson regression models to estimate trends and heterogeneity in SIRs within the study cohort by categories of sex, age at time of first cancer diagnosis (15-49 years, 50-64 years, 65-84 years, and 85 years), period of first diagnosis (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, and 2005-2009 ), follow-up interval (<1 year, 1-4 years, 5-9 years, and 10 years), and first cancer site. 10, 22 The P value for trend was estimated using the likelihood ratio test. We also analyzed the data using negative binomial regression to test the robustness of the Poisson regression model. Because the results were nearly identical, herein we only present results derived from the Poisson regression model. A 2-sided P value <.05 was considered to be statistically significant. All analyses were performed using Stata software (version 12; StataCorp LLC, College Station, Texas).
RESULTS
Characteristics of the Study Population
A total of 5339 SPCs were identified among the 51,803 eligible patients with cancer who accumulated 347,830 Table S1 ).
SPCs at Any Site
For the entire study period, the SIR of any SPC was 1.06 (95% CI, 1.03-1.09) and the AER was 8. (Table 2 ). We performed a sensitivity analysis to examine the effect of including SPCs occurring within 2 months of a first cancer diagnosis and of excluding SPCs occurring within 4 months of a first cancer diagnosis on SIRs by 5-year calendar periods. Both the overall SIRs and the time patterns were similar There was a significantly increasing temporal trend in the SIRs for any SPC, with adjustments for patient sex, age at time of first diagnosis, follow-up interval, and first cancer type (adjusted P for trend <.001) (Fig. 1) . We checked the trends across single calendar years and found a significantly increasing trend in SPC risk in the multivariable Poisson model (P for trend <.001). We also assessed potential nonlinear associations in the model. The goodness of fit did not significantly improve after adding a quadratic term for single-year to the model (likelihood ratio test, P 5.6826), therefore suggesting a linear trend across single-year periods. The multivariable Poisson models revealed that age at the time of first cancer diagnosis, period of first diagnosis, and first cancer type were independently associated with the risk of any SPC (all P values <.05) (see Supporting Information Table S2 ). To reduce the risk of residual confounding due to different followup intervals, we assessed the pattern of risk over time after restricting the follow-up interval for all cases to a maximum of 9 years. The same patterns were apparent for SIRs by period of first cancer diagnosis and in the multivariable Poisson model adjusting for sex, age at time of first cancer diagnosis, and first cancer types. Analysis by specific first cancer type demonstrated various changes in SPC risk over time (Table 3) . The SIRs for all SPCs were highest for individuals with a first cancer diagnosis of head and neck cancer in 2005 through 2009 and the trend in SIRs increased over time (P for trend 5.040). The trends in SIRs for any SPC also increased over time for individuals with a first diagnosis of skin cancer, prostate cancer, and cancers of the urinary tract (all P for trend <.05).
SPCs at Specific Sites
For individuals with a first diagnosis of any cancer type, the SIRs for a second cancer of the digestive tract including colorectal cancer were significantly elevated in more recent periods compared with earlier periods (all P for trend <.05) ( Table 4 ). The SIRs for prostate cancer after any first cancer tended to decline over time. However, after adjustment for age at first diagnosis, follow-up interval, and first cancer type, the risk of prostate cancer as an SPC increased significantly over time (adjusted P for trend 5 .013) (Fig. 1) . Individuals with any first cancer diagnosis in recent periods also were more likely to have an SPC diagnosis of head and neck cancer, digestive cancer (including colorectal cancer), and lung cancer compared with earlier periods after adjusting for sex, age at the time of first diagnosis, follow-up interval, and first cancer type (all adjusted P for trend <.05) (Fig. 1) . Table 5 shows SIR and AER estimates for SPCs after a first cancer diagnosis in 1980 through 1989, 1990 through 1999, and 2000 through 2009 for specific first cancer and SPC types when the observed number of relevant SPCs was at least 50 and the AER value for at least 1 of the 3 periods was >5 cases per 10,000 PYR. For individuals with a first diagnosis of head and neck cancer, lung cancer accounted for the largest AER in both the earlier and more recent periods but AERs for prostate cancer demonstrated the greatest increase in AERs from 1980 Figure 1 . Ratio of standardized incidence ratios (SIRs) for all second primary cancers (SPCs) and specific SPC types after any first cancer by calendar period of first cancer diagnosis (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, and 2005-2009 ) with adjustment for sex (not for female organs and prostate), age at time of first cancer diagnosis, follow-up interval, and first cancer type. P values were derived from multivariable Poisson regression models with adjustment for sex (not for female organs and prostate), age at time of first cancer diagnosis, follow-up interval, and first cancer type. *For digestive cancers, colorectal cancers were excluded. 95% CI indicates 95% confidence interval. Original Article 
DISCUSSION
In this population-based study with >30 years of surveillance, the risk of SPC continued to increase beyond 2000 among survivors of adult-onset cancer after accounting for background cancer occurrence in the general population and patient characteristics (sex, age at time of first cancer diagnosis, follow-up interval, and first cancer type) within the study cohort. In particular, the SPC burden due to prostate cancer increased greatly in male survivors of head and neck cancer, skin cancer, and cancers of the urinary tract. Site-specific time trends in SPC risk may reveal changing patterns of medical surveillance after a first cancer diagnosis. Several factors need to be considered when interpreting the results of the current study. First, some SPCs may be misclassified as metastases and vice versa. This issue is inevitable in clinical practice and may be more intractable when new cancers arise at the same site and with the same morphology as the first cancer. Applying IARC rules helped to partially avoid this issue because SPCs that originate in the same site and with the same morphology as the first cancer were excluded. As such, using IARC rules resulted in coding fewer SPCs compared with using other coding rules (eg, Surveillance, Epidemiology, and End Results [SEER] rules) for paired organs (eg, breast cancer) and therefore produced lower SIR values. 24 Second, the first cancers diagnosed in 1980 through 1984 might be second or higher-order cancer in a few cases. The TCR was established in 1978 but records were not as complete in the first 2 years. Third, the TCR did not record cancer risk factors, treatment data, and follow-up procedures, thereby making it difficult to investigate the factors that might have contributed to the increase in SPC risk over time. Fourth, the exclusion of SPCs occurring within 2 months of a first cancer diagnosis may have introduced error but our sensitivity analysis including all SPCs and excluding SPCs occurring within 4 months demonstrated similar results. In addition, there is the possibility that multiple testing of stratified data may increase the likelihood of significant differences by chance alone.
Previous studies have reported a substantially elevated risk of SPCs among survivors of head and neck cancer, with head and neck cancer and lung cancer reported to account for the largest SPC burden. 23, 25 We confirmed these findings in the current study and reported novel findings of increasing temporal trends in the risk of head and neck cancer and lung cancer among all cancer survivors during 1980 through 2009. This finding coincided with the gradual increase of head and neck and chest computed tomography scanning in Tasmania since 1994, and thus may reflect the improved detection of SPCs at these sites. In addition, improvements in imaging techniques may have allowed for the better identification of SPCs that previously were believed to be metastases. It is important to note that in the current study, risks of smokingrelated SPCs continued to increase and remain high in individuals with a smoking-related first primary cancer. Elevated SPC risks in these survivors might be explained by increased smoking prevalence among these individuals. 26 The decreasing trends of tobacco-related cancer incidence in the general Australian population since the 1980s also may contribute to the increase in SIRs. The decline in expected tobacco-related cancers (the SIR denominator) would lead to a consequent slight increase in relevant SIRs over time. 13 An important finding was the large increase in AERs for prostate cancer among survivors of specific cancer types from 2000 onward. A recent meta-analysis combining 20 studies reported more frequent screening for breast, cervical, colorectal, and prostate cancers among cancer survivors compared with noncancer controls. However, all the evidence came from North America and the United Kingdom. 11 In Tasmania, Medicare (Australia's publicly funded universal health care system) records demonstrated a dramatic increase in prostate-specific antigen (PSA) testing between 1994 and 2013, from 3647 of 100,000 men to 16,572 of 100,000 men, respectively. 27 Thus our findings of increases in the AER for prostate cancer among male survivors of head and neck cancer, skin cancer, and cancers of the urinary tract may indicate increased screening for prostate cancer among these cancer survivors. The benefits of PSA testing remain controversial given the potential for the overdiagnosis of prostate cancer. 28 
Original Article
For all cancer survivors, the risk of an SPC of the prostate was lower than expected in the general population, most likely due to the low risk of a second prostate cancer after radical treatment of a first prostate cancer. Survivors of prostate cancer accounted for the largest percentage of all cancer survivors in the current study but we only observed 2 second prostate cancer cases among them. In comparison, there were 419.9 cases expected assuming general population incidence rates. After excluding males with a first prostate cancer, the SIR for prostate cancer among all cancer survivors was significantly higher (SIR, 1.16; 95% CI, 1.08-1.25). This finding also could explain the reversal of trend in SIRs for prostate cancer after any first cancer in the multivariable regression model. The SIR values were decreasing over time, whereas the trend in SIRs was increasing over time after adjusting for first cancer type and other patient characteristics including age at time of first cancer diagnosis and follow-up interval. We performed additional analyses excluding SPCs occurring in the same site as the first cancer. The SIR values increased from 1. Table S3 ). Although the SIR values increased in each period, the time pattern of SIR values and ratio of SIRs in the multivariable Poisson model were nearly identical to the main results of the current study.
The increasing temporal trend in the risk of colorectal SPCs may reflect increased screening for colorectal cancer among cancer survivors. There was some evidence that cancer survivors were more likely to receive SPC screening if their first cancer was detected by screening. 29 PSA testing and national cervical and bowel cancer screening programs were implemented in Australia in 1987, 1991, and 2006, respectively. 13 In the current study, colorectal cancer accounted for the largest AER of SPCs among survivors of first cancers of the female organs and prostate during 2000 through 2009. Intensive screening for colorectal cancer among these cancer survivors may be a possible explanation, especially if their first cancers (cervical cancer or prostate cancer) were detected by screening. Another possible cause is the increased use of abdomen/pelvic computed tomography as one of the follow-up procedures for survivors of cancers of the female organs. Alternatively, patients may more actively pursue screening given the known benefits. Additional studies are needed to investigate whether variations in the mode of second cancer ascertainment explain temporal trends in diagnosis.
Findings from SEER data and Australian data previously observed increasing trends in the overall SPC risks from the 1970s and 1980s to 2000. 3, 4 A recent study of SEER data reported the SPC risk from 1992 through 2008 but did not assess time patterns and did report SIRs to allow for comparisons with previous findings. 30 One Italian study reported nearly constant SIR values in Italy from 1978 to 2010. 5 However, they did not report changes in SIRs with adjustment for patient characteristics (sex, age at time of first cancer diagnosis, follow-up interval, and first cancer type). The association between these patient characteristics and the risk of SPCs has been identified in recent studies. 6, 22 The current study observed an increasing trend in SPC risk from 1980 through 2000 that was consistent with previous findings in the United States and Australia and reported novel findings of a continued increasing trend in SPC risk from 2000 onward in multivariable models. The TCR data also have their own advantage due to the relative stable population (less outmigration), and therefore less underascertainment of SPCs. 16 However, there were likely to be some SPCs missing from our analysis as a result of migration out of Tasmania to other parts of Australia or beyond. An investigation of data held in the Australian Cancer Database determined that in our study period the percentage of all Tasmanian cancer cases with a subsequent primary cancer registered in another Australian state or territory was very small (0.34%; unpublished data).
The trend in the risk of SPCs among survivors of adult-onset cancer has continued to increase over the last 30 years. Although the patterns of increasing risk generally were consistent with developments in medical imaging and screening programs for some cancer types, to our knowledge the degree to which this explains the increase in SPC risk remains uncertain. The increase in prostate SPC burden among survivors of specific cancer types may reflect active PSA testing. Patient anxiety and overestimation of the benefits and underestimation of the potential harms of prostate cancer screening could lead to overdiagnosis. 12, 28 Further studies are needed to quantify the potential overdiagnosis of SPC among cancer survivors, and thus to assess whether there is potential for optimizing follow-up strategies.
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